ATE184480T1 - Verfahren zur herstellung von arzneizubereitungen mit verzögerter wirkstoffabgabe - Google Patents

Verfahren zur herstellung von arzneizubereitungen mit verzögerter wirkstoffabgabe

Info

Publication number
ATE184480T1
ATE184480T1 AT94304933T AT94304933T ATE184480T1 AT E184480 T1 ATE184480 T1 AT E184480T1 AT 94304933 T AT94304933 T AT 94304933T AT 94304933 T AT94304933 T AT 94304933T AT E184480 T1 ATE184480 T1 AT E184480T1
Authority
AT
Austria
Prior art keywords
water
soluble polypeptide
active ingredients
delayed release
medicinal preparations
Prior art date
Application number
AT94304933T
Other languages
English (en)
Inventor
Yasutaka Igari
Kazumichi Yamamoto
Kayoko Okamoto
Yutaka Yamagata
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of ATE184480T1 publication Critical patent/ATE184480T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT94304933T 1993-07-05 1994-07-05 Verfahren zur herstellung von arzneizubereitungen mit verzögerter wirkstoffabgabe ATE184480T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP16579393 1993-07-05
JP8176594 1994-04-20

Publications (1)

Publication Number Publication Date
ATE184480T1 true ATE184480T1 (de) 1999-10-15

Family

ID=26422772

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94304933T ATE184480T1 (de) 1993-07-05 1994-07-05 Verfahren zur herstellung von arzneizubereitungen mit verzögerter wirkstoffabgabe

Country Status (11)

Country Link
US (1) US5534269A (de)
EP (1) EP0633020B1 (de)
KR (1) KR950002748A (de)
CN (1) CN1106653A (de)
AT (1) ATE184480T1 (de)
AU (1) AU674077B2 (de)
CA (1) CA2127317C (de)
DE (1) DE69420632T2 (de)
FI (1) FI943205A (de)
NO (1) NO942515L (de)
NZ (1) NZ260909A (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5656297A (en) * 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
US5711968A (en) 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6790439B1 (en) * 1995-06-07 2004-09-14 Zymogenetics, Inc. Thrombopoietin compositions
ATE268591T1 (de) * 1995-06-27 2004-06-15 Takeda Chemical Industries Ltd Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung
CA2230494A1 (en) * 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics Inc. Composition for sustained release of an agent
US6265389B1 (en) 1995-08-31 2001-07-24 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of oligonucleotides
US6190702B1 (en) 1996-03-28 2001-02-20 Takeda Chemical Industries, Ltd. Sustained-released material prepared by dispersing a lyophilized polypeptide in an oil phase
DE69719367T2 (de) 1996-12-20 2003-10-16 Takeda Chemical Industries Ltd Verfahren zur herstellung einer zusammensetzung mit verzoegerter abgabe
US5945126A (en) * 1997-02-13 1999-08-31 Oakwood Laboratories L.L.C. Continuous microsphere process
US6656508B2 (en) 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
US6191107B1 (en) 1997-09-26 2001-02-20 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc
KR100595340B1 (ko) * 1998-01-21 2006-07-03 다케다 야쿠힌 고교 가부시키가이샤 서방형 제제의 동결 건조법
DK1061948T3 (da) 1998-03-20 2003-03-31 Takeda Chemical Industries Ltd Præparat til vedvarende frigivelse af et fysiologisk aktivt polypeptid samt fremstilling deraf
FR2778847A1 (fr) * 1998-05-20 1999-11-26 Jean Pierre Perraud Implant injectable en sous gingival resorbable, constitue de microspheres a liberation prolongee et chargees en principes actifs et en suspension dans un gel vecteur
US6165509A (en) * 1998-09-01 2000-12-26 University Of Washington Pegylated drug complexed with bioadhesive polymer suitable for drug delivery and methods relating thereto
US6270802B1 (en) 1998-10-28 2001-08-07 Oakwood Laboratories L.L.C. Method and apparatus for formulating microspheres and microcapsules
FR2793684B1 (fr) * 1999-05-17 2001-08-10 Ethypharm Lab Prod Ethiques Utilisation de microspheres biodegradables liberant un agent anticancereux pour le traitement du glioblastome, procede de preparation de ces microspheres et suspension les contenant
AU6875900A (en) 1999-09-08 2001-04-10 Chugai Seiyaku Kabushiki Kaisha Protein solution preparation and method of stabilizing the same
EP1219298A4 (de) 1999-09-17 2003-06-11 Takeda Chemical Industries Ltd Verfahren zur herstellung von proteinpulver
US7582311B1 (en) 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
US7651703B2 (en) 1999-10-15 2010-01-26 Genentech, Inc. Injection vehicle for polymer-based formulations
EP1329224A4 (de) * 2000-09-01 2004-04-14 Chugai Pharmaceutical Co Ltd Über lange zeit stabilisierte lösungen
US8637077B2 (en) 2000-12-28 2014-01-28 Takeda Pharmaceutical Company Limited Sustained-release preparation
WO2003000282A1 (en) 2001-06-21 2003-01-03 Genentech, Inc. Sustained release formulation
TWI225416B (en) * 2001-06-29 2004-12-21 Takeda Chemical Industries Ltd Sustained-release composition and process for producing the same
WO2003055470A1 (fr) * 2001-12-26 2003-07-10 Takeda Chemical Industries, Ltd. Nouvelle microsphere et son procede de production
US8519008B2 (en) 2003-01-22 2013-08-27 Purina Animal Nutrition Llc Method and composition for improving the health of young monogastric mammals
US20070207211A1 (en) * 2003-04-10 2007-09-06 Pr Pharmaceuticals, Inc. Emulsion-based microparticles and methods for the production thereof
JP2007515392A (ja) 2003-04-10 2007-06-14 ピーアール ファーマシューティカルズ，インコーポレイテッド エマルジョンベースの微粒子の製造のための方法
DK1633440T3 (da) * 2003-04-15 2008-09-08 Opperbas Holding Bv Farmaceutisk sammensætning omfattende proteiner og/eller polypeptider og kolloidale partikler
JP5165239B2 (ja) * 2003-07-15 2013-03-21 ピーアール ファーマシューティカルズ， インコーポレイテッド 制御放出処方物の調製のための方法
ES2741576T3 (es) * 2003-07-23 2020-02-11 Evonik Corp Composiciones de liberación controlada
TW200613012A (en) * 2004-07-02 2006-05-01 Takeda Pharmaceuticals Co Sustained-release composition, process for producing the same and use of the same
DE102004046102B4 (de) 2004-09-23 2009-09-03 Mars Inc. Indikatorgranulat
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
CN101199623B (zh) * 2006-12-16 2011-04-27 石茂光 治疗高血压药物缓控释制剂的制备方法
EP2167039B1 (de) * 2007-05-18 2016-09-28 Durect Corporation Verbesserte depot-formulierungen
CA2687979C (en) 2007-05-25 2017-07-04 Tolmar Therapeutics, Inc. Sustained delivery formulations of risperidone compounds
GB201016436D0 (en) 2010-09-30 2010-11-17 Q Chip Ltd Method of making solid beads
GB201016433D0 (en) 2010-09-30 2010-11-17 Q Chip Ltd Apparatus and method for making solid beads
US20140308352A1 (en) 2013-03-11 2014-10-16 Zogenix Inc. Compositions and methods involving polymer, solvent, and high viscosity liquid carrier material
US9737605B2 (en) 2013-03-11 2017-08-22 Durect Corporation Injectable controlled release composition comprising high viscosity liquid carrier
CN104288123B (zh) * 2014-10-27 2016-09-14 浙江理工大学 一种负载干扰素微胶囊的制备方法
CN110404115B (zh) * 2019-07-23 2022-03-18 广东省医疗器械研究所 一种具有表面坑洞的碳酸盐/可降解高分子微球及其制备方法与应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
US4832686A (en) * 1986-06-24 1989-05-23 Anderson Mark E Method for administering interleukin-2
JP3116311B2 (ja) * 1990-06-13 2000-12-11 エーザイ株式会社 マイクロスフィアの製法
IE912365A1 (en) * 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US5171579A (en) * 1991-10-11 1992-12-15 Genetics Institute, Inc. Formulations of blood clot-polymer matrix for delivery of osteogenic proteins
WO1993015722A1 (en) * 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles

Also Published As

Publication number Publication date
FI943205A0 (fi) 1994-07-05
AU6614594A (en) 1995-01-12
CN1106653A (zh) 1995-08-16
FI943205A (fi) 1995-01-06
NZ260909A (en) 1995-04-27
CA2127317A1 (en) 1995-01-06
CA2127317C (en) 2008-10-07
AU674077B2 (en) 1996-12-05
US5534269A (en) 1996-07-09
NO942515L (no) 1995-01-06
KR950002748A (ko) 1995-02-16
NO942515D0 (no) 1994-07-04
DE69420632T2 (de) 2000-03-02
DE69420632D1 (de) 1999-10-21
EP0633020A1 (de) 1995-01-11
EP0633020B1 (de) 1999-09-15

Similar Documents

Publication Publication Date Title
ATE184480T1 (de) Verfahren zur herstellung von arzneizubereitungen mit verzögerter wirkstoffabgabe
EP0158277A3 (de) Implantierbare Zubereitungen von regulatorischen Peptiden mit gesteuerter Freisetzung und Verfahren zur ihrer Herstellung
ATE101340T1 (de) Neue arzneimittelformulierung sowie verfahren zu deren herstellung.
ATE178616T1 (de) Verfahren zur herstellung von biologisch aktivem protein (z.b. tgf)
DE3481170D1 (de) Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung.
DE69704426D1 (de) Verfahren zur herstellung von medizinischem kaugummi mit einem guten geschmack, enthaltend eine einschlussverbindung
ATA151587A (de) Verfahren zur herstellung einer pharmazeutischen kapsel zur oralen verabreichung mit verzögerter wirkstofffreisetzung bzw. kombinierter verzögerter/rascher wirkstofffreisetzung
DE69033874D1 (de) Verfahren zur Herstellung von arzneimittelenthaltenden gefriergetrockneten Formulierungen
ATE233088T1 (de) Verfahren zur herstellung einer zusammensetzung mit verzoegerter abgabe
DE3872382D1 (de) Pharmazeutische zusammensetzungen mit verlaengerter wirkung und verfahren zu ihrer herstellung.
ATE135375T1 (de) Glykosaminoglykan-modifiertes protein, verfahren zu dessen herstellung und pharmazeutische zubereitungen, die es enthalten
PT78710B (de) Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung
ATE149826T1 (de) Verfahren zur herstellung von festen pharmazeutischen retardformen
DE69129899D1 (de) Verfahren zur Herstellung von D-Alpha-Aminosäuren
DE69009237D1 (de) Verfahren zur Herstellung von optisch aktiven Estern der 6-t-Butoxy-3,5-dihydroxyhexansäure.
FR2768341B1 (fr) Composition pharmaceutique placebo lyophilisable destinee a imiter un medicament, notamment a base de proteines ou de polypeptides
DE58907182D1 (de) Verfahren zur Herstellung von 6-Aminocapronsäureestern.
DE68917937D1 (de) Verbindungen mit magensäureinhibitorwirkung und verfahren zur herstellung.
DE68924011D1 (de) Verfahren zur Herstellung von Pyrazolkarbonsäure und Derivaten.
DE68915310D1 (de) Verfahren zur Herstellung von enantiomerischen homogenen Aminopyrrolidinyl-naphthyridin- und Quinoloncarbonsäuren.
DE69808938T2 (de) Verfahren zur herstellung von pharmazeutischen zusammensetzungen
DE59604613D1 (de) Verfahren zur herstellung von optisch aktiven alpha-aminosäuren und alpha-aminosäure-derivaten
DE58908961D1 (de) Verfahren zur Isolierung von 2-Keto-polyhydroxy-C6-carbonsäuren, insbesondere von 2-Keto-L-gulonsäure aus wässrigen Fermentationsausträgen.
DE58909208D1 (de) Verfahren zur Herstellung von Imidazol-2-carbonsäuren.
ATE92459T1 (de) Verfahren zur herstellung von optisch aktiven 2- arylpropionsaeuren.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties